Actively Recruiting

Phase 2
Age: 18Years - 65Years
All Genders
NCT06225232

Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study

Led by McMaster University · Updated on 2025-03-19

16

Participants Needed

1

Research Sites

65 weeks

Total Duration

On this page

Sponsors

M

McMaster University

Lead Sponsor

C

Center for Medicinal Cannabis Research

Collaborating Sponsor

AI-Summary

What this Trial Is About

Cannabis is the most commonly used psychoactive substance in Canada (Lowry \& Corsi, 2020). A sub-group of cannabis users develop a condition known as Cannabis Use Disorder (CUD), which is defined as a regular pattern of cannabis use that causes performance difficulty at work, school and relationships (Hasin et al., 2013). A review of current treatments available for CUD indicate the lack of a pharmacological and psychological treatment with high success rates, which highlights the importance of exploring potential psychosocial interventions for the treatment of CUD. Given the evidence of psilocybin's therapeutic potential in the treatment of substance use disorders (de Veen et al., 2017), we aim to conduct a study using psilocybin-assisted-psychotherapy in the treatment of CUD. The study aims to evaluate the feasibility, safety, tolerability and potential therapeutic effect of 2 doses \[25 mg\] of psilocybin administered as part of an 8-week Motivational Enhancement Therapy (MET) and supportive therapy. This trial will be the first to evaluate the potential treatment effects of psilocybin on symptoms of CUD.

CONDITIONS

Official Title

Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed informed consent form.
  • Able to show proof of identity.
  • Fluent in English for speaking and reading, able to complete assessments.
  • Age between 18 and 65 years.
  • Diagnosed with at least moderate Cannabis Use Disorder.
  • Desire to reduce or stop cannabis use.
  • Medically healthy based on blood tests, liver and kidney function tests, ECG, and physician review.
  • Stable living situation for the study duration.
  • Willing to follow study rules and procedures.
  • Agree to regular medical check-ins and reporting of any side effects.
  • If female of childbearing potential, agree to use effective birth control methods during the study.
  • If male, agree to use condoms with spermicide and ensure partner uses effective contraception.
  • Agree to have a companion accompany and stay with the participant overnight after dosing sessions.
Not Eligible

You will not qualify if you...

  • History of bipolar disorder, schizophrenia, psychotic disorders, personality disorders, delirium, dementia, or cognitive disorders.
  • First-degree relatives with schizophrenia, bipolar disorder, or psychosis.
  • Diagnosis of panic disorder or seizure disorders.
  • Dependence on substances other than cannabis or tobacco in the past 6 months.
  • Positive drug screen for substances other than cannabis.
  • Use of serotonergic psychedelics more than 5 times lifetime or in the past year.
  • Current use of psychotropic medications except stable doses of SSRIs or SNRIs.
  • History of cardiovascular disease, uncontrolled hypertension, or other risky medical conditions.
  • Receiving psychotherapy for Cannabis Use Disorder concurrently.
  • Serious suicide or homicide risk or recent suicidal behaviors.
  • Positive pregnancy test, pregnant, breastfeeding, or not using birth control if of childbearing potential.
  • Unable to understand study risks and benefits or give informed consent.
  • Participating or planning to participate in other interventional clinical trials during this study.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

MacAnxiety Research Centre

Hamilton, Ontario, Canada, L8S 1B8

Actively Recruiting

Loading map...

Research Team

M

Maryam Rahat, Ph.D Candiate

CONTACT

B

Beth Patterson

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here